NASDAQ:MBRX

Moleculin Biotech Stock Predictions

Healthcare > Biotechnology

Buy MBRX

*Your capital is at risk

$2.75

-0.370 (-11.86%)

At Close: Jun 23, 2026

Currently predicting for Wed, 24 Jun 2026

MBRX Live board

Community Bull/Bear

Target Next close

Join the MBRX prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

MBRX Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For MBRX

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

MBRX Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT MOLECULIN BIOTECH INC

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	18.12%	Jun 12
DHI $146.71	6.29%	Jun 10
PHM $118.49	6.02%	Jun 10
EAT $140.46	17.09%	Jun 05
E ETD $20.67	3.19%	Jun 05

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by